Wedbush analyst Laura Chico lowered the firm's price target on PepGen to $4 from $5 and keeps an Outperform rating on the shares. Most important in the Q1 update from PepGen, the company completed recruitment in the 10mg/kg multi-dose cohort in the FREEDOM2 study of PGN-EDODM1, the firm notes. This keeps data readout timing intact for the second half of 2026. Recall, the earlier 5mg/kg PGN-EDODM1 multi-dose readout raised some questions after splicing data demonstrated variability. Wedbush was encouraged drug concentrations increased over time, but may need to see additional signals from functional assessments.
